Similar articles

• A possible role of 18F-FDG positron-emission tomography scanning in the early detection of rituximab-induced pneumonitis in patients with non-Hodgkin's lymphoma.

  Nieuwenhuizen L, Verzijlbergen FJ, Wiltink E, Grutters JC, Biesma DH. Nieuwenhuizen L, et al. Haematologica. 2008 Aug;93(8):1267-9. doi: 10.3324/haematol.12802. Epub 2008 Jun 12. Haematologica. 2008. PMID: 18556403 No abstract available.
• [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy.

  Kalkanis D, Stefanovic A, Paes F, Escalon MP, Serafini A, Lossos IS. Kalkanis D, et al. Leuk Lymphoma. 2009 Jun;50(6):904-11. doi: 10.1080/10428190902919200. Leuk Lymphoma. 2009. PMID: 19455459
• Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.

  Qiao W, Zhao J, Wang C, Wang T, Xing Y. Qiao W, et al. Hematology. 2010 Feb;15(1):21-7. doi: 10.1179/102453310X12583347009739. Hematology. 2010. PMID: 20132658 Clinical Trial.
• The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.

  Qiu L, Chen Y, Wu J. Qiu L, et al. Hell J Nucl Med. 2013 Sep-Dec;16(3):230-6. doi: 10.1967/s0024499100091. Epub 2013 Oct 2. Hell J Nucl Med. 2013. PMID: 24137577 Review.
• PET/CT for therapy response assessment in lymphoma.

  Hutchings M, Barrington SF. Hutchings M, et al. J Nucl Med. 2009 May;50 Suppl 1:21S-30S. doi: 10.2967/jnumed.108.057190. Epub 2009 Apr 20. J Nucl Med. 2009. PMID: 19380407 Review.